About 600 reports

Disease modifying antirheumatic drugs are further sub-segmented into corticosteroids, antimalarial, methotrexate, and others.

  • Autoimmune Disease
  • Healthcare
  • Therapy
  • World
  • Market Size
  • 12.1 BIBLIOGRAPHY

REV PRESS., ##(##), PP. ##-##.

  • Healthcare
  • Demand
  • Forecast
  • Pfizer Inc.
  • Sanofi S.A.
  • SAARDS SALES VOLUME AND MARKET SHARE
  • CHAPTER IV ARTHRITIS TREATMENT DRUGS PRODUCTION AND DEMAND

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Healthcare
  • China
  • Demand
  • Trade
  • Ltd Sichuan Xichangyangtian Pharmaceutical Co.

Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 ##.

  • Arthritis
  • Healthcare
  • APAC
  • World
  • Company Financials
  • PHYSICAL THERAPY
  • 12.2 ABBREVIATIONS

BMJ SPECIALIST JOURNALS, ##(SUPPL ##), P.

  • Healthcare
  • United States
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • SAARDS SALES VOLUME AND MARKET SHARE
  • IV. ARTHRITIS TREATMENT DRUGS PRODUCTION AND

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Healthcare
  • China
  • Demand
  • Bayer AG
  • Yunnan Baiyao Group Co., Ltd.
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
  • BARICITINIB - DRUG PROFILE

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Cancer
  • Healthcare
  • United States
  • Product Initiative
  • Incyte Corporation
  • Dermira Raises USD7.5 Million in Private Placement of Shares

The two pivotal trials, CLAREOS-## and CLAREOS-##, enrolled a total of ##, ## patients.

  • Healthcare
  • Pharmaceutical
  • United States
  • Company
  • Dermira, Inc.
  • TOFACITINIB CITRATE ER - DRUG PROFILE
  • JUN 28, 2018: XELJANZ (TOFACITINIB CITRATE) RECEIVES MARKETING AUTHORIZATION IN THE EUROPEAN UNION FOR ACTIVE PSORIATIC ARTHRITIS

Patients with moderately to severely active RA who had an inadequate response to at least one disease- modifying antirheumatic drug (DMARD) received tasocitinib ## mg or ## mg monotherapy or placebo twice a day.

  • Healthcare
  • Research And Development
  • United States
  • Product Initiative
  • Pfizer Inc.
  • DERMIRA RAISES USD7.5 MILLION IN PRIVATE PLACEMENT OF SHARES

One such project, led by Dr.

  • Autoimmune Disease
  • Healthcare
  • Pharmaceutical
  • United States
  • UCB S.A.
  • Cardiovascular Diseases

one of the world' s leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally.

  • Analgesic
  • Biomarker
  • Healthcare
  • Immunodiagnostics
  • Firalis SAS

Global Market Study on Rheumatoid Arthritis Treatment: Trends Indicate the Prevalence of New Combination Treatment and Dual Inhibitors ##.

  • Arthritis
  • Healthcare
  • APAC
  • World
  • Market Size

Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

  • Arthritis
  • Chronic Disease
  • Healthcare
  • World
  • Market Size

The transaction will be effective on April ##, 2017.

  • Healthcare
  • Pharmaceutical
  • Japan
  • M&A
  • Taisho Pharmaceutical Co., Ltd.
  • AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2016-2023 (USD BILLION)
  • 6.2 RHEUMATOID ARTHRITIS

Glucagon-like peptide-##, commonly known as GLP-##, is a hormone produced by the proglucagon gene in the L-cells of the gut.

  • Diabetes
  • Healthcare
  • Injectable Delivery
  • United States
  • Amgen Inc.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Hair Growth
  • Healthcare
  • Pharmaceutical
  • United States
  • Product Initiative
  • Melanocortin Receptor 4 (MC4R) - Product Development Milestones

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Healthcare
  • United States
  • World
  • Product Initiative
  • Palatin Technologies, Inc.
  • colitis (UC).
  • Dec 14, 2017: Pfizer Announces FDA Approval Of Xeljanz (Tofacitinib) For The Treatment Of Active Psoriatic Arthritis

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • United States

According to recent findings published in the Annals of the Rheumatic Diseases, disease activity and the use of biological disease-modifying anti-rheumatic drugs among patients with RA vary from country to country, due to different contributing factors, such as per capita GDP, drug affordab

  • Biosimilar
  • Healthcare
  • United Kingdom
  • Company
  • Celltrion, Inc.
  • RABEXIMODUM - DRUG PROFILE

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Healthcare
  • Hospital
  • Immunotherapy
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • Santen Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Plan Details ##.

  • Healthcare
  • Japan
  • United States
  • Company
  • Santen Pharmaceutical Co., Ltd.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • SARILUMAB - DRUG PROFILE

Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

  • Biosimilar
  • Healthcare
  • United States
  • Company Operations
  • Product Initiative

Truxima in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor

  • Autoimmune Disease
  • Healthcare
  • Pharmaceutical
  • Therapy
  • ChemoCentryx, Inc.
  • TOFACITINIB CITRATE ER - DRUG PROFILE
  • SEP 08, 2017: NICE ISSUES POSITIVE RECOMMENDATION FOR XELJANZ (TOFACITINIB CITRATE) AS A NEW TREATMENT OPTION FOR ADULTS WITH SEVERE RHEUMATOID ARTHRITIS

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying anti-rheumatic drug (cDMARD).

  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Autoimmune Disease
  • Healthcare
  • United States
  • World
  • Product Initiative
  • AND FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) WHO HAVE RESPONDED INADEQUATELY TO CONVENTIONAL THERAPY.
  • IXEKIZUMAB - DRUG PROFILE

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Healthcare
  • Therapy
  • United States
  • Product Initiative

The guidance does not recommend abatacept in combination with methotrexate, for treating rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying anti-rheumatic drugs (DMARDs) including methotrexate.

  • Healthcare
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Therapy
  • Galapagos NV

In more severe cases disease modifying anti-rheumatic drugs (DMARDs) may be prescribed.

  • Anti Rheumatic
  • Healthcare
  • Therapy
  • United States
  • World

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Healthcare
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative